Answers are grounded in this paper and cite their sources.
Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
No takes yet. Share an insight, caveat, or question.
McLornan et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: